CD274 and colon adenocarcinoma: Integrating CSRS with specific immune checkpoint inhibitors, such as those targeting PD-1/PD-L1 pathways, can refine the predictive biomarker framework, enabling more precise risk stratification and identification of effective therapeutic targets to bolster immune responses in COAD patients.